Rein Therapeutics Inc.

07/21/2026 | Press release | Distributed by Public on 07/21/2026 14:11

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders

On July 20, 2026, Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, for the purposes of:

•

Electing two Class III directors to serve on our Board of Directors until our 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified;

•

Approving an amendment to our restated certificate of incorporation to increase the number of authorized shares of common stock from 100 million shares to 200 million shares;

•

Ratifying the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the year ending December 31, 2026; and

•

Approving, on an advisory basis, the compensation of our named executive officers disclosed in the Proxy Statement.

Our stockholders elected two Class III directors, namely Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D., with shares voted as follows:

Name

For

Withheld

Broker

Non-Votes

Josef H. von Rickenbach

25,402,442 13,202,963 25,098,629

Reinhard J. Ambros, Ph.D

25,404,238 13,201,167 25,098,629

In addition, our stockholders approved an amendment to our restated certificate of incorporation to increase the number of authorized shares of common stock from 100 million shares to 200 million shares, with shares voted as follows:

For

61,004,221

Against

2,394,208

Abstain

305,605

There were no broker non-votes on the approval of the above amendment to our restated certificate of incorporation.

In addition, our stockholders ratified the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the year ending December 31, 2026, with shares voted as follows:

For

62,953,351

Against

172,420

Abstain

578,263

There were no broker non-votes on the ratification of our independent registered public accounting firm.

In addition, our stockholders approved, on an advisory basis, the compensation of our named executive officers disclosed in the Proxy Statement, with shares voted as follows:

For

37,628,483

Against

914,331

Abstain

62,591

There were 25,098,629 broker non-votes on the approval, on an advisory basis, of the compensation of our named executive officers.

Rein Therapeutics Inc. published this content on July 21, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 21, 2026 at 20:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]